Literature DB >> 8357285

Early administration of heme arginate for acute porphyric attacks.

P Mustajoki1, Y Nordmann.   

Abstract

BACKGROUND: We investigated the efficacy of early administration of heme arginate in acute porphyric attacks.
METHODS: The series consisted of 51 consecutive acute attacks in 22 patients with acute intermittent porphyria and in two patients with variegate porphyria referred to a hospital in France or in Finland. Four attacks were associated with pareses, and 47 attacks were not. Heme in a dose of 250 mg or 3 mg/kg was started within 24 hours after admission in 37 (72.5%) of the attacks and within 4 days in 49 (96%) of the attacks. During all except five attacks, four daily infusions were given.
RESULTS: The mean (+/- SD) duration of abdominal or nonabdominal pain was 2.5 +/- 0.97 days, and opiates were stopped an average of 2.8 +/- 0.72 days after the first heme infusion was started. All patients responded. In 46 (90%) of the attacks, the total hospitalization time was 7 days or less. The mean urinary excretion of porphobilinogen decreased to 16.2% +/- 7.7% and that of 5-aminolevulinic acid to 11.6% +/- 5.6% of pretreatment values. The only side effect was moderate thrombophlebitis in one patient.
CONCLUSION: Favorable responses in every attack suggest specific effects of heme. In patients with acute attacks, heme therapy should be started immediately on admission.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8357285

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  26 in total

Review 1.  Diagnosis and management of porphyria.

Authors:  H Thadani; A Deacon; T Peters
Journal:  BMJ       Date:  2000-06-17

2.  [A 25-year-old patient with colonic pseudo-obstruction, hyponatremia, hypertension, and diffuse pain].

Authors:  Philipp Lutz; Daniel Maring; Henriette J Tschampa; Tilman Sauerbruch
Journal:  Med Klin (Munich)       Date:  2010-04

3.  Acute intermittent porphyria: fatal complications of treatment.

Authors:  P E Stein; M N Badminton; J H Barth; D C Rees; R Sarkany; M F Stewart; T M Cox
Journal:  Clin Med (Lond)       Date:  2012-06       Impact factor: 2.659

Review 4.  Porphyrias at a glance: diagnosis and treatment.

Authors:  Maria Domenica Cappellini; Valentina Brancaleoni; Giovanna Graziadei; Dario Tavazzi; Elena Di Pierro
Journal:  Intern Emerg Med       Date:  2010-10       Impact factor: 3.397

5.  Clinical features predictive of a poor prognosis in acute porphyria.

Authors:  Elena Pischik; Anton Bulyanitsa; Valery Kazakov; Raili Kauppinen
Journal:  J Neurol       Date:  2004-12       Impact factor: 4.849

6.  [Cortical amaurosis and status epilepticus with acute porphyria].

Authors:  T Wessels; F Blaes; C Röttger; M Hügens; S Hüge; M Jauss
Journal:  Nervenarzt       Date:  2005-08       Impact factor: 1.214

7.  Differential effects of metalloporphyrins on messenger RNA levels of delta-aminolevulinate synthase and heme oxygenase. Studies in cultured chick embryo liver cells.

Authors:  E E Cable; J A Pepe; N C Karamitsios; R W Lambrecht; H L Bonkovsky
Journal:  J Clin Invest       Date:  1994-08       Impact factor: 14.808

Review 8.  [Hepatic porphyrias and alcohol].

Authors:  M O Doss; A Kühnel; U Gross; I Sieg
Journal:  Med Klin (Munich)       Date:  1999-06-15

Review 9.  [Porphyrias-what is verified?]

Authors:  U Stölzel; I Kubisch; T Stauch
Journal:  Internist (Berl)       Date:  2018-12       Impact factor: 0.743

Review 10.  Erythropoietic and hepatic porphyrias.

Authors:  U Gross; G F Hoffmann; M O Doss
Journal:  J Inherit Metab Dis       Date:  2000-11       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.